AGL 37.80 Increased By ▲ 0.30 (0.8%)
AIRLINK 218.50 Decreased By ▼ -4.39 (-1.97%)
BOP 10.93 Increased By ▲ 0.11 (1.02%)
CNERGY 7.57 Increased By ▲ 0.01 (0.13%)
DCL 9.16 Decreased By ▼ -0.26 (-2.76%)
DFML 40.35 Decreased By ▼ -0.61 (-1.49%)
DGKC 102.11 Decreased By ▼ -4.65 (-4.36%)
FCCL 34.95 Decreased By ▼ -2.12 (-5.72%)
FFL 19.50 Increased By ▲ 0.26 (1.35%)
HASCOL 12.70 Decreased By ▼ -0.48 (-3.64%)
HUBC 131.00 Decreased By ▼ -1.64 (-1.24%)
HUMNL 14.59 Decreased By ▼ -0.14 (-0.95%)
KEL 5.19 Decreased By ▼ -0.21 (-3.89%)
KOSM 7.35 Decreased By ▼ -0.13 (-1.74%)
MLCF 45.80 Decreased By ▼ -2.38 (-4.94%)
NBP 66.04 Decreased By ▼ -0.25 (-0.38%)
OGDC 223.50 Increased By ▲ 0.24 (0.11%)
PAEL 44.30 Increased By ▲ 0.80 (1.84%)
PIBTL 9.01 Decreased By ▼ -0.06 (-0.66%)
PPL 194.00 Decreased By ▼ -4.24 (-2.14%)
PRL 43.50 Increased By ▲ 1.26 (2.98%)
PTC 26.62 Decreased By ▼ -0.77 (-2.81%)
SEARL 107.00 Decreased By ▼ -3.08 (-2.8%)
TELE 10.14 Decreased By ▼ -0.38 (-3.61%)
TOMCL 35.95 Decreased By ▼ -0.67 (-1.83%)
TPLP 14.58 Decreased By ▼ -0.37 (-2.47%)
TREET 25.98 Decreased By ▼ -0.55 (-2.07%)
TRG 67.40 Decreased By ▼ -1.45 (-2.11%)
UNITY 33.59 Decreased By ▼ -0.60 (-1.75%)
WTL 1.73 Decreased By ▼ -0.06 (-3.35%)
BR100 12,397 Increased By 33.3 (0.27%)
BR30 37,347 Decreased By -871.2 (-2.28%)
KSE100 117,587 Increased By 467.3 (0.4%)
KSE30 37,065 Increased By 128 (0.35%)
Business & Finance

Pfizer to pursue bringing COVID-19 vaccine to India after import relaxation

  • "We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.
  • "We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."
Published April 13, 2021

NEW DELHI: Pfizer Inc said on Tuesday it would work towards bringing the COVID-19 vaccine it developed with Germany's BioNTech to India after the government eased import rules, after withdrawing its application in February.

"We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.

"We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."

Comments

Comments are closed.